#### **PCT REQUEST**

#### Original (for SUBMISSION)

	In the second second		
0	For receiving Office use only		
0-1	International Application No.		
0-2	International Filing Date		
0-3	Name of receiving Office and "PCT International Application"		
0-4	Form PCT/RO/101 PCT Request		
0-4-1	Prepared Using	PCT-SAFE [EASY mode]	
0-5	Petition	Version 3.50 (Build 0002.162)	
	The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty		
0-6	Receiving Office (specified by the applicant)	United Kingdom Patent Office (RO/GB)	
0-7	Applicant's or agent's file reference		
1	Title of Invention	QUINAZOLINE DERIVATIVES	
II Applicant			
11-1	This person is applicant only		
		AP: (BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW); EA: (AM AZ BY KG KZ MD RU TJ TM); EP: (AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR); OA: (BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG); AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW	
11-4	Name	(	
11-5	Address	ASTRAZENECA AB Sodertalje	
		SE-151 85 Sweden	
1-6	State of nationality.	SE	
1-7	State of regidence	SE	
1-8	Telephone No.	+44 1625 230148	
1-9	Eaccimile No.		
	<u> </u>	+46 8553 28820	

#### **PCT REQUEST**

#### Original (for SUBMISSION )

111-1	Applicant and/or inventor		
III-1-1	This person is	applicant only	
III-1-2	Applicant for	MG	
III-1- <b>4</b>	Name	ASTRAZENECA UK LIMITED	
III-1-5	Address	15 Stanhope Gate London Greater London W1K 1LN United Kingdom	
III-1-6	State of nationality	GB	
III-1-7	State of residence	GB	
III-2	Applicant and/or inventor		
III-2-1	This person is	applicant and inventor	
III-2 <b>-2</b>	Applicant for	US only	
III-2 <del>-</del> 4	Name (LAST, First)	HENNEQUIN, Laurent, François, Andre	
III-2-5	Address	AstraZeneca Pharma  Z.I. la Pompelle, BP 1050  51689 Reims  France	
III-2-6	State of nationality	FR	
III-2-7	State of residence	FR	
111-3	Applicant and/or inventor		
III-3-1	This person is	applicant and inventor	
111-3-2	Applicant for	US only	
III-3-4	Name (LAST, First)	HALSALL, Christopher, Thomas	
III-3-5	Address	AstraZeneca R&D Alderley Alderley Park Macclesfield Cheshire SK10 4TG United Kingdom	
11-3-6	State of nationality	GB	
11-3-7	State of residence	GB	

#### **PCT REQUEST**

#### Original (for SUBMISSION)

IV-1	Agent or common representative; or address for correspondence	
	The person identified below is hereby/ has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name	ASTRAZENECA
IV-1-2	Address	Global Intellectual Property SE-151 85 Sodertalje Sweden
IV-1-3	Telephone No.	+44 1625 230148
IV-1-4	Facsimile No.	+46 8553 28820
V	DESIGNATIONS	10 0000 20020
V-1	The filing of this request constitutes under Rule 4.9(a), the designation of all Contracting States bound by the PCT on the international filing date, for the grant of every kind of protection available and, where applicable, for the grant of both regional and national patents.	
VI-1	Priority claim of earlier national application	
√I-1-1	Filing date	16 September 2003 (16.09.2003)
/i-1-2	Number	0321620.7
√l-1-3	Country	GB
<b>∕</b> 1-2	Priority claim of earlier national application	
/l-2-1	Filing date	19 March 2004 (19.03.2004)
/1-2-2	Number	0406163.6
/1-2-3	Country	GB
/II-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)
<b>/111</b>	Declarations	Number of declarations
'111-1	Declaration as to the identity of the inventor	-
'III-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-
111-3	date, to claim the priority of the earlier application	-
III-4	purposes of the designation of the United States of America)	
III-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	

 $C_{i,j}$ 

#### PCT REQUEST

#### Original (for SUBMISSION)

IX	Check list	number of sheets	electronic file(s) attached
X-1	Request (including declaration sheets)	5	1
X-2	Description	129	
X-3	Claims	19	
X-4	Abstract	1	1
K-5	Drawings	0	
X-7	TOTAL	154	
	Accompanying Items	paper document(s) attached	electronic file(s) attached
X-8	Fee calculation sheet	1	-
X-9	Original separate power of attorney	1	•
(-10	Original general power of attorney		<del></del>
(-13	Priority document(s)	Item(s) VI-1 VI-2	-
(-17	PCT-SAFE physical media	-	
(-19	Figure of the drawings which should accompany the abstract		•
(-20	Language of filing of the international application	English	
<del>-1</del>	Signature of applicant, agent or common representative	M	
-1-1	Name	ASTRAZENECA	
-1-2	Name of signatory	NELSON, Michael Andrew	
-1-3	Capacity	Agent	

## FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

5/5

#### **PCT REQUEST**

#### Original (for SUBMISSION)

# FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by	
	the International Bureau	
	<del></del>	

# 1/1 PCT REQUEST (ANNEX - FEE CALCULATION SHEET) Original (for SUBMISSION) (This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only			
0-1	International Application No.			
0-2	Date stamp of the receiving Office			
	<u> </u>			
0-4	Form PCT/RO/101 (Annex)	<del></del>	· · · · · · · · · · · · · · · · · · ·	
<b>-</b>	PCT Fee Calculation Sheet			
0-4-1	Prepared Using	PCT-SAFE [EAS	Y model	
		Version 3.50	(Build 0002.16	:21
0-9	Applicant's or agent's file reference	101211-1 WO	12414 0002.16	04)
2	Applicant	ASTRAZENECA A	В	
12	Calculation of prescribed fees	fee amount/muliplier	Total amounts (GBP)	T
12-1	Transmittal fee T	₽	55	<del> </del>
12-2-1	Search fee S		1078	L
12-2-2	International search to be carried out by		1078	<u> </u>
12-3	International filing fee (first 30 sheets)			
12-4	(first 30 sheets) [1] Remaining sheets	028		
12-5		124		
12-6	Total additional amount  2			
12-7	i1 + i2 =	800	,	
12-12	EASY Filing reduction R	1496		
12-13	Total International filing fee (i-R)	- 43		
12-14	Fee for priority document	□ □	1451	·
	Number of priority documents requested	o		
12-15		22		
12-16	Total priority document fee: P	4		
2-17	TOTAL FEES PAYABLE (T+S+I+P)	\$	2504	
2-19	Mode of payment	- I	2584	
2-20	Deposit account instructions	authorization	to charge depo	osit account
	paposit accoditt instructions			
	The receiving Office	United Kingdom	Patent Office	RO/GB)
- 1	Authorization to charge the total fees indicated above	✓		(100, 02,
	Authorization to charge any deficiency or credit any overpayment in the total fees indicated above	1	•	
2-20-3		/		
	2	D02934		
2-22		10 September 2004 (10.09.2004)		
2-23	Name and signature	Jennifer Bennett		
				/

#### Original (for SUBMISSION)

13-2-3	Validation messages Names	Yellow! Agent 1 would not appear to be competent to act before the receiving Office	
	Validation messages Names	Green? Applicant 1:City missing	
13-2-7	Validation messages Contents	Green? The international application contains no drawings. Please verify.	
13-2-8	Validation messages Fees	Green? Please confirm that fee schedule utilized is the latest available	
13-2-9	Validation messages Payment	Green? Please ensure that you have a valid deposit account with the receiving Office selected.	

#### **ABSTRACT**

( :

The invention concerns quinazoline derivatives of the Formula I:

(A chemical formula should be inserted here - please see paper copy enclosed herewith)

wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing ar anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase

## PATENT COOPERATION TREATY

Appointment of Agent or Common Representative

The undersigned applicants HALSALL Christopher Thomas and HENNEQUIN Laurent Francois Andre hereby appoint

ÅS SIVBORG, Susanne; ANDERSSON, Kerstin; BENNETT, Jennifer; BERRY, Ian Gordon; BILL, Kevin; BOAR, Robin; BRYANT, Tracey; BURNS, Tracy; CELEBIOGLU, Sonya; COCHRAN, Karen Elizabeth; DENERLEY, Paul Millington; DIXON, Helen Jane; DOUGLAS, Shirley Andrea; FARQUHARSON, Andrew; FREDRIKSSON, Gunilla; FRENCH, Philip; GAINEY, Laurence David Scott; GILBERT, George Anthony; GILES, Allen Frank; GRIFFITHS-JOHNSON, Anna; HADLEY, John; HUDSON, Janette; HÄLLGREN, Christer; JANSSON, Anne; JÖNSSON, Jenny; KONDRAD, Karen Haggerty; LARSSON, Birgitta; LINDEROTH, Margareta; MACK, John Richard; MASON, Katie Louise; MILLER, Thomas; MITCHELL, Kenneth Frank; NELSON, Michael; PADGET, Lucy; PHILLIPS, Neil Godfrey Alasdair; QUARTIN, Robin Sandra; REMMER, Jane; SAMUELSSON, Britta; SKEPPSTEDT, Anita; STANSFIELD, Kevin; STERNAS, Ann-Sofie; SUMMERSELL, Richard; TAIT, Brian Steele; THOMAS, Mair; TIERNEY, Francis; TINSLEY, Rachel; WAHLSTRÖM, Christer; WALLIN IDSTAM,

with address AstraZeneca AB, Global Intellectual Property, SE-151 85 Södertälje, Sweden

[X] as agent

[] as common representative

to act on their behalf before the competent International Authorities in connection with the International application concerning

QUINAZOLINE DERIVATIVES

Macclesfield, Cheshire, SKIO 4TG-UK. 13th August 2004

( ...

HALSALL Christopher Thomas

(AVREW, FRANCOS ANDRE HEUVE PUIN HENNEQUIN Laurent François Andre

#### **PCT**

# General Power of Attorney (for several international applications filed under the Patent Cooperation Treaty)

We, AstraZeneca AB of 151 85 Sodertalje, Sweden, hereby authorise:

ÅS SIVBORG, Susanne ANDERSSON, Kerstin BENNETT, Jennifer Charlene BERRY, Ian Gordon BILL, Kevin

BOAR, Robin BRYANT, Tracey BURNS, Tracy Anne CELEBIOGLU, Sonya COCHRAN, Karen Elizabeth

DENERLEY, Paul Millington DIXON, Helen Jane DOUGLAS, Shirley Andrea FARQUHARSON, Andrew FREDRIKSSON, Gunilla

FRENCH, Philip Joseph
GAINEY, Laurence David Scott
GILBERT, George Anthony
GILES, Allen Frank
GRIFFITHS-JOHNSON, Anna

HADLEY, John HUDSON, Janette Mary HÄLLGREN, Christer JANSSON, Anne JÖNSSON, Jenny KONDRAD, Karen Haggerty LARSSON, Birgitta LINDEROTH, Margareta MACK, John Richard

MASON, Katie Louise MILLER, Thomas Kerr MITCHELL, Kenneth NELSON, Michael Andrew PADGET, Lucy Clare

PHILLIPS, Neil Godfrey Alasdair QUARTIN, Robin Sandra REMMER, Jane SAMUELSSON, Britta SKEPPSTEDT, Anita

SOMLO, Tommy STANSFIELD, Kevin STERNÅS, Ann-Sofie SUMMERSELL, Richard TAIT, Brian Steele

THOMAS, Mair Denise TIERNEY, Francis John TINSLEY, Rachel Maria WAHLSTRÖM, Christer WALLIN INDSTAM, Åsa

with address Global Intellectual Property, AstraZeneca AB, SE-151 85 Sodertalje, Sweden

to represent and duly sign for AstraZeneca AB in everything that concerns British and International patent applications, design applications and applications divided or separated therefrom as well as patents and designs based thereupon. This authorisation includes the authority to accept writs of indictment or summonses and other documents in proceedings and matters concerning the application, patent or design.

Sodertalje, Sweden – 26<sup>th</sup> August 2004

AstraZeneca AB

Kevin Bill, Authorised Officer

BEST AVAILABLE COPY

#### **PCT**

#### General Power of Attorney

(for several international applications filed under the Patent Cooperation Treaty)

We, AstraZeneca UK Limited of 15 Stanhope Gate, London W1K 1LN, United Kingdom, hereby authorise:

ÅS SIVBORG, Susanne ANDERSSON, Kerstin BENNETT, Jennifer Charlene BERRY, Ian Gordon BILL, Kevin

BOAR, Robin BRYANT, Tracey BURNS, Tracy Anne CELEBIOGLU, Sonya COCHRAN, Karen Elizabeth

DENERLEY, Paul Millington DIXON, Helen Jane DOUGLAS, Shirley Andrea FARQUHARSON, Andrew FREDRIKSSON, Gunilla

FRENCH, Philip Joseph GAINEY, Laurence David Scott GILBERT, George Anthony GILES, Allen Frank GRIFFITHS-JOHNSON, Anna

HADLEY, John HUDSON, Janette Mary HÄLLGREN, Christer JANSSON, Anne JÖNSSON, Jenny KONDRAD, Karen Haggerty LARSSON, Birgitta LINDEROTH, Margareta MACK, John Richard

MASON, Katie Louise MILLER, Thomas Kerr MITCHELL, Kenneth NELSON, Michael Andrew PADGET, Lucy Clare

PHILLIPS, Neil Godfrey Alasdair QUARTIN, Robin Sandra REMMER, Jane SAMUELSSON, Britta SKEPPSTEDT, Anita

SOMLO, Tommy STANSFIELD, Kevin STERNAS, Ann-Sofie SUMMERSELL, Richard TAIT, Brian Steele

THOMAS, Mair Denise TIERNEY, Francis John TINSLEY, Rachel Maria WAHLSTRÖM, Christer WALLIN INDSTAM, Åsa

with address Global Intellectual Property, AstraZeneca AB, SE-151 85 Sodertalje, Sweden

to represent and duly sign for AstraZeneca UK Limited in everything that concerns British and International patent applications, design applications and applications divided or separated therefrom as well as patents and designs based thereupon. This authorisation includes the authority to accept writs of indictment or summonses and other documents in proceedings and matters concerning the application, patent or design.

Sodertalje, Sweden - 26th August 2004

AstraZeneca UK Limited

Kevin Bill, Authorised Officer

BEST AVAILABLE COPY